ArticleDiabetology international2025
Is once-weekly insulin a viable alternative for type 2 diabetes? A meta-analysis of randomized controlled trials.
Article in Diabetology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of once-weekly insulins in type 2 diabetes: A systematic review and meta-analysis.Diabetes, obesity & metabolism · 2026 · on this mapPooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Once-weekly novel insulin preparations such as Icodec and basal insulin Fc (BIF)/insulin Efsitora Alfa have raised hope among clinicians and patients when they were developed and evaluated in a series of clinical trials. However, there were conflicting results regarding their efficacy and safety. This meta-analysis was carried out to evaluate the efficacy and safety of once-weekly insulin in patients with Type 2 diabetes mellitus (T2DM). Methods: PubMed/MEDLINE, Cochrane database, Scopus, and WHO International Clinical Trials Registry Platform (ICTRP) were searched till November 2024 for randomized controlled trials (RCTs). Our literature search found 2759 articles, out of which 11 studies with 11 reports were included in the meta-analysis as per eligibility criteria. Results: 5799 participants from 11 RCTs were included. Once-weekly insulin showed significant reduction of HbA1c, and pooled mean difference of once-weekly insulin vs once-daily insulin was - 0.09 (95% CI - 0.16 to - 0.02). Subgroup analysis revealed that Icodec - 0.12 (95% CI - 0.20 to - 0.04) was found to be superior, whereas BIF was found to be non-inferior 0.01 (95% CI - 0.11 to 0.13) compared to once-daily insulin regimen in reduction of HbA1c in T2DM. No significant differences were observed between once-weekly and once-daily insulin for other safety outcomes. Conclusions: Once-weekly insulin regimen was superior in reducing HbA1c level while maintaining a similar safety profile to the once-daily insulin regimen, thus suggesting that such regimen may potentially be an alternative to the currently established once-daily basal insulin regimen. Graphical abstract:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.